Skip to main content
Top
Published in: Insights into Imaging 1/2023

Open Access 01-12-2023 | Magnetic Resonance Imaging | Original Article

Predicting histologic differentiation of solitary hepatocellular carcinoma up to 5 cm on gadoxetate disodium-enhanced MRI

Authors: Ting Yang, Hong Wei, Yuanan Wu, Yun Qin, Jie Chen, Hanyu Jiang, Bin Song

Published in: Insights into Imaging | Issue 1/2023

Login to get access

Abstract

Background

To establish a preoperative score based on gadoxetate disodium-enhanced magnetic resonance imaging (EOB-MRI) and clinical indicators for predicting histologic differentiation of solitary HCC up to 5 cm.

Methods

From July 2015 to January 2022, consecutive patients with surgically proven solitary HCC measuring ≤ 5 cm at preoperative EOB-MRI were retrospectively enrolled. All MR images were independently evaluated by two radiologists who were blinded to all clinical and pathologic information. Univariate and multivariate logistic regression analyses were performed to identify significant clinicoradiological features associated with poorly differentiated (PD) HCC, which were then incorporated into the predictive score. The predictive score was validated in an independent validation set by area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and accuracy.

Results

A total of 182 patients were included, 42 (23%) with PD HCC. According to the multivariate analysis, marked hepatobiliary phase hypointensity (odds ratio [OR], 9.98), LR-M category (OR, 5.60), and serum alpha-fetoprotein (AFP) level > 400 ng/mL (OR, 3.58) were incorporated into the predictive model; the predictive score achieved an AUC of 0.802 and 0.830 on the training and validation sets, respectively. The sensitivity, specificity, and accuracy of the predictive score were 66.7%, 85.7%, and 81.3%, respectively, on the training set and 66.7%, 81.0%, and 77.8%, respectively, on the validation set.

Conclusion

The proposed score integrating two EOB-MRI features and AFP level can accurately predict PD HCC in the preoperative setting.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–24CrossRef Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–24CrossRef
2.
go back to reference Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156(2):477–491CrossRef Kulik L, El-Serag HB (2019) Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156(2):477–491CrossRef
3.
go back to reference Ruff SM, Rothermel LD, Diggs LP et al (2020) Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB (Oxford) 22(7):1004–1010CrossRef Ruff SM, Rothermel LD, Diggs LP et al (2020) Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection. HPB (Oxford) 22(7):1004–1010CrossRef
4.
go back to reference Decaens T, Roudot-Thoraval F, Badran H et al (2011) Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int 31(6):792–801CrossRef Decaens T, Roudot-Thoraval F, Badran H et al (2011) Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma. Liver Int 31(6):792–801CrossRef
5.
go back to reference Lu Z, Sun Z, Liu C et al (2021) Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study. BMC Cancer 21(1):751CrossRef Lu Z, Sun Z, Liu C et al (2021) Prognostic nomogram for hepatocellular carcinoma with radiofrequency ablation: a retrospective cohort study. BMC Cancer 21(1):751CrossRef
6.
go back to reference Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 267(3):776–786CrossRef Choi JW, Lee JM, Kim SJ et al (2013) Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 267(3):776–786CrossRef
7.
go back to reference Haimerl M, Utpatel K, Götz A et al (2021) Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade. Sci Rep 11(1):22991CrossRef Haimerl M, Utpatel K, Götz A et al (2021) Quantification of contrast agent uptake in the hepatobiliary phase helps to differentiate hepatocellular carcinoma grade. Sci Rep 11(1):22991CrossRef
8.
go back to reference Peng Z, Jiang M, Cai H et al (2016) Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma. BMC Cancer 16:625CrossRef Peng Z, Jiang M, Cai H et al (2016) Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with T1 mapping predicts the degree of differentiation in hepatocellular carcinoma. BMC Cancer 16:625CrossRef
9.
go back to reference Huang K, Dong Z, Cai H et al (2019) Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer 19(1):364CrossRef Huang K, Dong Z, Cai H et al (2019) Imaging biomarkers for well and moderate hepatocellular carcinoma: preoperative magnetic resonance image and histopathological correlation. BMC Cancer 19(1):364CrossRef
10.
go back to reference Witjes CDM, Willemssen FEJA, Verheij J et al (2012) Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. J Magn Reson Imaging 36(3):641–647CrossRef Witjes CDM, Willemssen FEJA, Verheij J et al (2012) Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI. J Magn Reson Imaging 36(3):641–647CrossRef
11.
go back to reference Rong D, Liu W, Kuang S et al (2021) Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI. Eur Radiol 31(10):7584–7593CrossRef Rong D, Liu W, Kuang S et al (2021) Preoperative prediction of pathologic grade of HCC on gadobenate dimeglumine-enhanced dynamic MRI. Eur Radiol 31(10):7584–7593CrossRef
12.
go back to reference Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81–94CrossRef Dagogo-Jack I, Shaw AT (2018) Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol 15(2):81–94CrossRef
13.
go back to reference Friemel J, Rechsteiner M, Frick L et al (2015) Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res 21(8):1951–1961CrossRef Friemel J, Rechsteiner M, Frick L et al (2015) Intratumor heterogeneity in hepatocellular carcinoma. Clin Cancer Res 21(8):1951–1961CrossRef
15.
go back to reference Chou Y, Lao I, Hsieh P et al (2019) Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma. World J Gastroenterol 25(21):2636–2649CrossRef Chou Y, Lao I, Hsieh P et al (2019) Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma. World J Gastroenterol 25(21):2636–2649CrossRef
17.
go back to reference Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195(1):13–28CrossRef Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195(1):13–28CrossRef
18.
go back to reference Shin J, Lee S, Kim SS et al (2021) Characteristics and early recurrence of hepatocellular carcinomas categorized asLR-M: comparison with those categorized as LR-4 or 5. J Magn Reson Imaging 54(5):1446–1454CrossRef Shin J, Lee S, Kim SS et al (2021) Characteristics and early recurrence of hepatocellular carcinomas categorized asLR-M: comparison with those categorized as LR-4 or 5. J Magn Reson Imaging 54(5):1446–1454CrossRef
19.
go back to reference Choi SY, Kim SH, Park CK et al (2018) Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study. Radiology 286(3):897–908CrossRef Choi SY, Kim SH, Park CK et al (2018) Imaging features of gadoxetic acid-enhanced and diffusion-weighted MR imaging for identifying cytokeratin 19-positive hepatocellular carcinoma: a retrospective observational study. Radiology 286(3):897–908CrossRef
20.
go back to reference Feng Z, Li H, Zhao H et al (2021) Preoperative CT for characterization of aggressive macrotrabecular-massive subtype and vessels that encapsulate tumor clusters pattern in hepatocellular carcinoma. Radiology 300(1):219–229CrossRef Feng Z, Li H, Zhao H et al (2021) Preoperative CT for characterization of aggressive macrotrabecular-massive subtype and vessels that encapsulate tumor clusters pattern in hepatocellular carcinoma. Radiology 300(1):219–229CrossRef
21.
go back to reference An C, Park S, Chung YE et al (2017) Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol 209(3):576–583CrossRef An C, Park S, Chung YE et al (2017) Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol 209(3):576–583CrossRef
22.
go back to reference Montal R, Andreu-Oller C, Bassaganyas L et al (2019) Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer 121(4):340–343CrossRef Montal R, Andreu-Oller C, Bassaganyas L et al (2019) Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials. Br J Cancer 121(4):340–343CrossRef
23.
go back to reference Jiang H, Wei J, Fu F et al (2022) Predicting microvascular invasion in hepatocellular carcinoma: a dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int 42(5):1158–1172CrossRef Jiang H, Wei J, Fu F et al (2022) Predicting microvascular invasion in hepatocellular carcinoma: a dual-institution study on gadoxetate disodium-enhanced MRI. Liver Int 42(5):1158–1172CrossRef
24.
go back to reference Mule S, Galletto PA, Tenenhaus A et al (2020) Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma. Radiology 295(3):562–571CrossRef Mule S, Galletto PA, Tenenhaus A et al (2020) Multiphase liver MRI for identifying the macrotrabecular-massive subtype of hepatocellular carcinoma. Radiology 295(3):562–571CrossRef
25.
go back to reference Kang HJ, Kim H, Lee DH et al (2021) Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology 300(3):572–582CrossRef Kang HJ, Kim H, Lee DH et al (2021) Gadoxetate-enhanced MRI features of proliferative hepatocellular carcinoma are prognostic after surgery. Radiology 300(3):572–582CrossRef
26.
go back to reference Ji GW, Zhu FP, Xu Q et al (2020) Radiomic features at contrast-enhanced CT Predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 294(3):568–579CrossRef Ji GW, Zhu FP, Xu Q et al (2020) Radiomic features at contrast-enhanced CT Predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 294(3):568–579CrossRef
27.
go back to reference Mehta N, Heimbach J, Harnois DM et al (2017) Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 3(4):493–500CrossRef Mehta N, Heimbach J, Harnois DM et al (2017) Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 3(4):493–500CrossRef
28.
go back to reference Zhu AX, Kang YK, Yen CJ et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282–296CrossRef Zhu AX, Kang YK, Yen CJ et al (2019) Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(2):282–296CrossRef
29.
go back to reference Shinkawa H, Tanaka S, Kabata D et al (2021) The prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma is dependent on tumor size. Liver Cancer 10(5):461–472CrossRef Shinkawa H, Tanaka S, Kabata D et al (2021) The prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma is dependent on tumor size. Liver Cancer 10(5):461–472CrossRef
30.
go back to reference Akateh C, Black SM, Conteh L et al (2019) Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 25(28):3704–3721CrossRef Akateh C, Black SM, Conteh L et al (2019) Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. World J Gastroenterol 25(28):3704–3721CrossRef
31.
go back to reference Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358–380CrossRef Heimbach JK, Kulik LM, Finn RS et al (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358–380CrossRef
32.
go back to reference Liao S, Su T, Jeng Y et al (2019) Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. Hepatology 69(1):209–221CrossRef Liao S, Su T, Jeng Y et al (2019) Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma. Hepatology 69(1):209–221CrossRef
Metadata
Title
Predicting histologic differentiation of solitary hepatocellular carcinoma up to 5 cm on gadoxetate disodium-enhanced MRI
Authors
Ting Yang
Hong Wei
Yuanan Wu
Yun Qin
Jie Chen
Hanyu Jiang
Bin Song
Publication date
01-12-2023
Publisher
Springer Vienna
Published in
Insights into Imaging / Issue 1/2023
Electronic ISSN: 1869-4101
DOI
https://doi.org/10.1186/s13244-022-01354-w

Other articles of this Issue 1/2023

Insights into Imaging 1/2023 Go to the issue